Influenza Vaccine Effectiveness in Preventing Outpatient, Inpatient, and Severe Cases of Laboratory-Confirmed InfluenzaJesús Castilla, Ferrán Barbé, Pere Godoy et al.|Clinical Infectious Diseases|2013Cited by 125
Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021Esther Kissling, Mariëtte Hooiveld, Virginia Martin et al.|Eurosurveillance|2021Cited by 55
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024Marine Maurel, Gloria Pérez‐Gimeno, Silke Buda et al.|Eurosurveillance|2024Cited by 50
Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre studyEsther Kissling, Francisco Pozo, Iván Martínez‐Baz et al.|Influenza and Other Respiratory Viruses|2022Cited by 45
Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre studyMarine Maurel, Francisco Pozo, Gloria Pérez‐Gimeno et al.|Influenza and Other Respiratory Viruses|2024Cited by 28